| Accession |
PRJCA011456 |
| Title |
Phase III trial of SR-1701 plus chemotherapy versus placebo plus chemotherapy for previously untreated advanced or metastatic gastric cancer or gastroesophageal junction cancer |
| Relevance |
Medical |
| Data types |
Clinical, imaging, metabolic, biomarker, gene data
|
| Organisms |
Homo sapiens
|
| Description |
To evaluate the safety and tolerability of SHR-1701 combined with CAPOX as first-line therapy in subjects with advanced or metastatic GC/GEJC, and to determine the recommended dose for phase II study |
| Sample scope |
Multiisolate |
| Release date |
2022-08-26 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| NA
|
|
NA
|
|
|
|
| Submitter |
weiqing ge
weiqing
ge (weiqing.ge@hengrui.com)
|
| Organization |
Jiangsu Hengrui pharmaceutical Co.LTD |
| Submission date |
2022-08-26 |
